A Phase 2 interventional study of natalizumab and interferon beta 1-a in Relapsing Remitting Multiple Sclerosis, sponsored by Biogen. Completed at 33 sites in 3 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-09-19.
Sponsored by Biogen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing natalizumab in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. Natalizumab · Multiple Sclerosis, Relapsing-Remitting.
Among the 21 studies testing natalizumab in Multiple Sclerosis, Relapsing-Remitting, this one is the 9th largest by enrollment, is one of 3 that started in 2010, is one of 4 in phase 2, and was the 10th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 21 studies testing natalizumab in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Natalizumab: first FDA approval 2004 (TYSABRI), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 110 across the 21 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 4 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen: none open now, 1 under way, 1 of them phase 3. Of 72 finished, 31 (43%) have results posted.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 28th largest by enrollment of the 59 interventional ones that give a count, is one of 7 that started in 2010, is one of 9 in phase 2, and was the 29th registered.
Biogen’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
1 of the studies testing natalizumab in Multiple Sclerosis, Relapsing-Remitting that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03535298The Cleveland ClinicDetermining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS | 2027-07-30 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing natalizumab in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 78 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, rater blinded trial in patients who interrupt treatment with natalizumab with or without being treated with other immunomodulatory drugs, or continue treatment with natalizumab.
The main purpose of this study is to find out the following, when participants stop taking natalizumab for 24 weeks:
This study will also explore how quickly the effects of natalizumab return after resuming natalizumab dosing.
Major criteria include:
Drug: natalizumab
Other: IV placebo
Drug: interferon beta 1-a · Drug: methylprednisolone · Drug: glatiramer acetate
300 mg intravenous every 4 weeks
30 ug intramuscular once per week
1000 mg intravenous every 4 weeks
placebo intravenous every 4 weeks
20 mg subcutaneous once daily
Time Course to Return of Radiological and/or Clinical Evidence of Multiple Sclerosis Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) and/or Clinical Relapse Rescue Criteria.
Rescue criteria were: 1) central reader MRI finding of 1 new gadolinium-enhancing (Gd+) lesion of \>0.8 cubic centimeters in volume or 2 or more Gd+ lesions of any size 2) clinical relapse. Clinical relapse was new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, as defined by: an increase of ≥1 grade in ≥2 functional scales of the Expanded Disability Status Scale (EDSS); an increase of ≥2 grades in 1 functional scale of the EDSS; or an increase of \>0.5 in EDSS if the previous EDSS was ≤5.5, or ≥0.5 if the previous EDSS was \>5.5
Time frame: 28 Weeks
Time Course to Return of Radiological Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) Rescue Criteria.
MRI rescue criteria were the presence of 1 new gadolinium-enhancing (Gd+) lesion of \>0.8 cubic centimeters in volume or 2 or more Gd+ lesions of any size, according to the central MRI reader.
Time frame: 28 Weeks
Date of first treatment: 31 March 2010. Date of study completion: 02 November 2011.
| Milestone | Intravenous Placebo | Natalizumab | Interferon β-1a | Glatiramer Acetate | Methylprednisolone |
|---|---|---|---|---|---|
| Started | 42 | 45 | 17 | 17 | 54 |
| Completed | 35 | 43 | 12 | 15 | 46 |
| Not completed | 7 | 2 | 5 | 2 | 8 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 0 | 2 | 0 | 3 |
| Withdrew: Physician decision | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Early rescue | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Subject moved | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Images not usable (motion) | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Did not meet eligibility criteria | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Did not want per protocol treatment | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Subject refused to continue | 1 | 0 | 0 | 0 | 0 |
Rescue criteria were: 1) central reader MRI finding of 1 new gadolinium-enhancing (Gd+) lesion of \>0.8 cubic centimeters in volume or 2 or more Gd+ lesions of any size 2) clinical relapse. Clinical relapse was new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, as defined by: an increase of ≥1 grade in ≥2 functional scales of the Expanded Disability Status Scale (EDSS); an increase of ≥2 grades in 1 functional scale of the EDSS; or an increase of \>0.5 in EDSS if the previous EDSS was ≤5.5, or ≥0.5 if the previous EDSS was \>5.5
| Percentage of subjects meeting criteria | Natalizumab | Intravenous Placebo | Interferon β-1a | Glatiramer Acetate | Methylprednisolone |
|---|---|---|---|---|---|
| Time Course to Return of Radiological and/or Clinical Evidence of Multiple Sclerosis Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) and/or Clinical Relapse Rescue Criteria. | 4.7 | 60.5 | 28.6 | 53.3 | 54.8 |
MRI rescue criteria were the presence of 1 new gadolinium-enhancing (Gd+) lesion of \>0.8 cubic centimeters in volume or 2 or more Gd+ lesions of any size, according to the central MRI reader.
| Percentage of subjects meeting criteria | Natalizumab | Intravenous Placebo | Interferon β-1a | Glatiramer Acetate | Methylprednisolone |
|---|---|---|---|---|---|
| Time Course to Return of Radiological Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) Rescue Criteria. | 0.0 | 52.5 | 8.3 | 49.7 | 46.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intravenous Placebo | — | — | — |
| Natalizumab | — | — | — |
| Interferon β-1a | — | — | — |
| Glatiramer Acetate | — | — | — |
| Methylprednisolone | — | — | — |
| Event | Intravenous Placebo | Natalizumab | Interferon β-1a | Glatiramer Acetate | Methylprednisolone |
|---|---|---|---|---|---|
| Multiple Sclerosis RelapseNervous system disorders | 0/42 | 0/45 | 0/17 | 1/17 | 0/54 |
| SyncopeNervous system disorders | 0/42 | 0/45 | 1/17 | 0/17 | 0/54 |
| PresyncopeNervous system disorders | 0/42 | 0/45 | 1/17 | 0/17 | 0/54 |
| Multiple SclerosisNervous system disorders | 1/42 | 0/45 | 0/17 | 0/17 | 0/54 |
| Chest PainGeneral disorders | 0/42 | 1/45 | 0/17 | 0/17 | 0/54 |
| Brain AbscessInfections and infestations | 0/42 | 0/45 | 0/17 | 0/17 | 1/54 |
| Event | Intravenous Placebo | Natalizumab | Interferon β-1a | Glatiramer Acetate | Methylprednisolone |
|---|---|---|---|---|---|
| INFLUENZA LIKE ILLNESSGeneral disorders | 0/42 | 0/45 | 5/17 | 1/17 | 0/54 |
| NASOPHARYNGITISInfections and infestations | 5/42 | 11/45 | 4/17 | 1/17 | 5/54 |
| MULTIPLE SCLEROSIS RELAPSENervous system disorders | 8/42 | 2/45 | 4/17 | 4/17 | 11/54 |
| HEADACHENervous system disorders | 3/42 | 8/45 | 1/17 | 1/17 | 3/54 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 6/42 | 3/45 | 0/17 | 3/17 | 6/54 |
| FATIGUEGeneral disorders | 6/42 | 2/45 | 1/17 | 2/17 | 2/54 |
| URINARY TRACT INFECTIONInfections and infestations | 5/42 | 1/45 | 2/17 | 1/17 | 2/54 |
| MUSCLE SPASMSMusculoskeletal and connective tissue disorders | 0/42 | 0/45 | 2/17 | 1/17 | 0/54 |
| POST LUMBAR PUNCTURE SYNDROMEInjury, poisoning and procedural complications | 1/42 | 0/45 | 2/17 | 0/17 | 2/54 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 1/42 | 3/45 | 0/17 | 2/17 | 1/54 |
| Age Continuous(Years) | Natalizumab | Intravenous Placebo | Interferon β-1a | Glatiramer Acetate | Methylprednisolone | Total |
|---|---|---|---|---|---|---|
| Mean | 41.2 ± 9.70 | 40.0 ± 10.36 | 45.1 ± 9.92 | 44.1 ± 7.85 | 40.1 ± 9.96 | 41.2 ± 9.85 |
| Sex: Female, Male(Participants) | Natalizumab | Intravenous Placebo | Interferon β-1a | Glatiramer Acetate | Methylprednisolone | Total |
|---|---|---|---|---|---|---|
| Female | 37 | 31 | 14 | 14 | 39 | 135 |
| Male | 8 | 11 | 3 | 3 | 15 | 40 |
The record gives a start of Mar 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Natalizumab · Interferon beta-1a · Methylprednisolone · Glatiramer
Multiple Sclerosis, Relapsing-Remitting →